$1M Gifted To Main Line Health For Scarless Healing Research

BRYN MAWR, PA — A Main Line Health researcher's work to advance scarless healing, even for age-associated chronic wounds, has led to a $1 million donation to Main Line Health.

Main Line Health's Ellen Heber-Katz, PhD, found a strain of laboratory mice that were able to generate new tissue, a trait thought to be lost to evolution.

Her mid-1990s discovery not only sparked hope for human scarless healing but triggered headlines worldwide.

Now, Heber-Katz's progress, who came to the Lankenau Institute for Medical Research (LIMR) (part of Main Line Health) with the mission to develop drugs activating the regeneration switch in humans, has attracted a $1 million donation aimed to support momentum toward this goal.

Heber-Katz was named inaugural chairholder of The Daniel B. and Florence E. Green Endowed Chair in Regenerative Medicine Research Wednesday night.

The chair was established with a $1 million gift from The Green Family Foundation, paired with a $1 million match from the Lankenau Medical Center Foundation through its matching initiative designed to encourage large-scale, transformational philanthropic commitments.

"I can’t tell you how grateful I am to receive this generous support," Heber-Katz said. "Years ago, when I discovered the potential for a treatment that would combat degenerative diseases and aging, I received a lot of pushback. But I persisted. Now, this gift will accelerate the timetable for testing in humans and, I firmly believe, bring a drug to market."

Heber-Katz has two key products near the stage for human testing.

One is a drug in the form of a hydrogel. She and a research colleague at the University of California-Berkeley received a patent for the drug, which would be injected under the skin and is aimed at restoring chronic skin wounds as well as tissue damaged by natural aging. Wounds often do not heal for older people.

The other is a suture infused with a compound that will limit scarring. LIMR has applied for domestic and international patents.

Heber-Katz also has a grant from the Department of Defense, whose interest was piqued by the possibility of healing wartime injuries such as lost fingers, hands and limbs.

She received funding from the National Institute of Dental and Craniofacial Research as well as she moved into treating bone loss from periodontal disease, a condition affecting a majority of Americans over their lifetimes.

LIMR President George Prendergast, PhD, called Heber-Katz’s program "perhaps the most forward-looking and provocative at the Institute" and said it may accomplish what stem cells have yet to do.

“Unlike most strategies for tissue regeneration, which are based on implanting or transplanting stem cells, Ellen’s approach offers an off-the-shelf option that represents true FDA-approvable medicine,” Dr. Prendergast said. “Perhaps even more intriguingly, she has found the application of her approach in aged animals seems to produce a rejuvenating effect, stimulating an anti-aging phenomenon. How durable this effect may be is not yet clear, but the key is we’ll soon be ready to do the studies.”

The Green Family Foundation said it is honored to establish the endowed chair and both "recognize and amplify the remarkable research efforts of Heber-Katz."

Heber-Katz achieved her first breakthrough in 1996. That’s when she discovered that a larger-than-usual strain of mice called MRL (Murphy Roths Large) could completely heal small holes in their ears without scarring (ear holes help to distinguish mice during research studies).

The tissue didn’t look like typical adult healing, instead appearing more embryonic.

Heber-Katz soon discovered that MRL mice could even generate brand new tissue in damaged hearts.

In the 2000s, her work sparked international headlines, including “Just like Terminator, mouse ears will be back” (Chicago Tribune), “‘Miracle mouse’ can grow back lost limbs” (London Sunday Times), and “For a strain of mice, hearts can regenerate” (New York Times).

Her research also inspired bestselling author James Rollins’ 2002 novel "Amazonia."

He made her work central to the plot and recorded a short video shown at last night’s ceremony to thank her.

Then, at the Wistar Institute, starting in 2006, Heber-Katz and colleagues defined a set of master molecules that control the pathway to tissue regeneration.

Prendergast hired her in 2016 to develop a drug to increase the presence of a master molecule called hypoxia-inducible factor 1 alpha (HIF-1a), which would activate tissue regeneration during the body’s healing response.